stockportfolio.pro
NeoGenomics, Inc. (NEO)
Healthcare · Diagnostics & Research · NasdaqCM
NeoGenomics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $231.81M | $240.25M | $276.74M | $408.83M | $444.45M | $484.33M | $509.73M | $591.64M | $660.57M | $727.33M |
| Gross profit | $98.10M | $101.96M | $127.27M | $196.84M | $185.89M | $187.06M | $187.90M | $244.60M | $290.10M | $314.29M |
| Net income | $-6.14M | $-396,000 | $2.64M | $8.01M | $4.17M | $-8.35M | $-144.25M | $-87.97M | $-78.73M | $-108.03M |
| Net margin | -2.6% | -0.2% | 1.0% | 2.0% | 0.9% | -1.7% | -28.3% | -14.9% | -11.9% | -14.9% |
Source: NeoGenomics, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
Explore 16 years of NeoGenomics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NEO in your portfolio →
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics, Inc. — frequently asked questions
What is NeoGenomics, Inc.'s revenue?
NeoGenomics, Inc. (NEO) reported revenue of $727.33M for fiscal year 2025, up 10.1% from the prior year, according to its SEC filings.
Is NeoGenomics, Inc. profitable?
No — NEO reported a net loss of $-108.03M in fiscal 2025.
What is NEO's P/E ratio?
NeoGenomics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is NeoGenomics, Inc. growing?
NEO's revenue grew at roughly 10.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from NeoGenomics, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.